GSK wins FDA nod on Boostrix use; India's Orchid ordered to close API plant on pollution;

@FiercePharma: Nine of 10 Big Pharmas cut sales reps in 2010. Report | Follow @FiercePharma

> The FDA has approved GlaxoSmithKline's Boostrix vaccine to prevent tetanus, diphtheria and whooping cough in people aged 65 and older. News

> Warner Chilcott said a U.S. federal court ordered a Boehringher Ingelheim unit not to launch a generic version of its inflammatory bowel treatment Asacol until Dec. 31. Story

> India's Orchid Chemicals & Pharmaceuticals said its API facility received a closure notice over disposal of solid waste, affecting its production of the antibiotic cephalosporin. Item

> Teva Pharmaceutical Industries faces two court hearings today. A U.S. court will consider the company's case against the developers of generic Copaxone, while a U.K. court will hear Pfizer's patent infringement case against Teva on Lipitor. Article

> Lonza, the world's biggest maker of drug ingredients, agreed to buy Arch Chemicals for $1.2 billion to create the global leader in the business of killing bacteria and fungi. Report

> Johnson & Johnson's Scios unit was charged by U.S. prosecutors with misbranding the heart drug Natrecor because the medicine's labeling allegedly lacked adequate directions for use. News

> Hikma Pharma said it purchased a significant minority interest in Hubei Haosun Pharmaceutical through the subscription of new equity for a cash consideration of $5 million. Item

> Dietary supplement manufacturer USANA Health Sciences Inc said it got approval from the FDA to make over-the-counter drugs. Article

> Belgian medical equipment and services company Arseus plans to buy a Brazilian peer for €51 million ($73 million) to secure the top spot in the world's largest pharmaceutical compound market. News

Biotech News

@FierceBiotech: Pfizer's potential offload of biz units could aid R&D prospects. Article | Follow @FierceBiotech

> Merrimack Pharma takes shot at $172.5M IPO with cancer contenders. Article 

> Sanofi MS drug shines, biotech strategy advances. Story

> Amgen widens cancer reach in $1B-plus Micromet deal. Item

Biotech IT News

> Two computational biology standouts honored. Report

> IBM cloud aids fight against superbugs. Story

> Health informatics giant Optum changes CEOs. Article

> Sequencing giant BGI advances in bioinformatics game. Report

> BioTox buys CRO Bio-Quant, eyes software integration. Story

> Biomolecular computer shows promise in detecting disease. Article

Medical Device News

> FDA may change premarket notification requirements for radiology devices. Report

> SurgiQuest closes $19M round. Piece

> QIAGEN amends offer for Cellestis, provides update on Ipsogen. News

> BD gets partial win in patent case. Story

> Medtronic advises doctors of pump problem. Article

> Medtronic buys two surgical products companies. Report

And Finally... An international research team has discovered a strain of gonorrhea resistant to all currently available antibiotics. Report

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.